Recently, the US Food and Drug Administration (FDA) approved some diagnostic markers for bladder cancers based on urine analysis, such as bladder tumor antigen (BTA) and nuclear matrix protein-22 (NMP-22) [25]. This evidence concerns the gene NUMA1 and urinary bladder cancer.